Naturally occurring human antibodies to alphavirus infection

天然存在的人类抗甲病毒感染抗体

基本信息

项目摘要

DESCRIPTION (provided by applicant): Alphaviruses are arthropod-transmitted viruses that cause medically-important human infections worldwide. Specific therapeutics for these viruses are lacking, and only experimental vaccines are available for these infections. In this Developmental/Exploratory Grant, we will generate and characterize in detail human anti- alphavirus antibodies, filling an unaddressed gap in our knowledge regarding the human antibody repertoire to alphavirus infection. Although past studies have characterized antibody responses to prototypical alphaviruses, such as Sindbis virus, in mice; little is known regarding the specific epitopes or the repertoire of human antibodies to natural alphavirus infection. We propose to use human hybridoma technology that has proven capable of generating potent neutralizing antibodies to each of the three 20th century pandemic viruses, despite the fact that each of these viruses circulated many years ago, to generate human antibodies to two medically important alphaviruses, Venezuelan equine encephalitis (VEE) and Mayaro (MAY) virus. We will obtain blood from a unique population of individuals from endemic areas of alphavirus transmission in Peru who have been definitively diagnosed with recent VEE or MAY virus infection. From the B cells of these individuals, we will generate human monoclonal antibodies that neutralize VEE and MAY viruses, and we will characterize in vitro and in vivo the human monoclonal antibodies. VEE and MAY viruses cause significant morbidity in Latin American countries and also pose threats to the United States. VEE virus alone accounts for as much as 7% of the supposed dengue fever cases in certain tropical regions and is considered a NIAID Category B priority pathogen whereas MAY virus causes recurrent incapacitating arthralgias that can last several months, similar to Chikungunya virus. Completion of this study will generate the first naturally- occurring human antibodies to VEE and MAY virus, providing insight into the antibody repertoire toward these important human pathogens. It will also seek to identify VEE and MAY virus-specific and more broadly cross- reactive (to other alphaviruses) antibodies and their epitopes. Such antibodies are potential therapeutics, and information regarding their epitopes, particularly cross-reactive epitopes, may suggest optimized vaccine approaches that may successfully target multiple alphaviruses.
描述(由申请方提供):甲病毒是节肢动物传播的病毒,在全球范围内引起医学上重要的人类感染。目前缺乏针对这些病毒的特定疗法,只有实验性疫苗可用于这些感染。在这项开发/探索性资助中,我们将生成并详细表征人抗甲病毒抗体,填补我们关于甲病毒感染的人抗体库知识中未解决的空白。尽管过去的研究已经表征了小鼠中对原型甲病毒(如辛德毕斯病毒)的抗体应答;但关于天然甲病毒感染的人抗体的特异性表位或库知之甚少。我们建议使用人杂交瘤技术,该技术已被证明能够产生针对三种20世纪世纪大流行病毒中的每一种的有效中和抗体,尽管这些病毒中的每一种都在多年前传播,以产生针对两种医学上重要的甲病毒(委内瑞拉马脑炎(VEE)和马亚罗(MAY)病毒)的人抗体。我们将从秘鲁甲病毒传播流行区的独特人群中采集血液,这些人群已明确诊断为近期VEE或MAY病毒感染。从这些个体的B细胞中,我们将产生中和VEE和MAY病毒的人单克隆抗体,并且我们将在体外和体内表征人单克隆抗体。VEE和MAY病毒在拉丁美洲国家造成严重的发病率,也对美国构成威胁。在某些热带地区,仅VEE病毒就占假定登革热病例的7%,并被认为是NIAID B类优先病原体,而MAY病毒引起可持续数月的复发性失能性关节痛,类似于基孔肯雅病毒。这项研究的完成将产生第一个天然存在的VEE和MAY病毒的人类抗体,提供对这些重要的人类病原体的抗体库的了解。它还将寻求鉴定VEE和MAY病毒特异性和更广泛的交叉反应性(对其他甲病毒)抗体及其表位。此类抗体是潜在的治疗剂,并且关于其表位(特别是交叉反应性表位)的信息可以建议可以成功靶向多种甲病毒的优化的疫苗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Patricia Veronica Aguilar其他文献

Patricia Veronica Aguilar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Patricia Veronica Aguilar', 18)}}的其他基金

Evolution of Mayaro virus and its impact on transmission by urban vectors
马亚罗病毒的进化及其对城市媒介传播的影响
  • 批准号:
    10753968
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
Thermostable Inactivated Potent Yellow Fever Vaccine
耐热灭活强效黄热病疫苗
  • 批准号:
    10325436
  • 财政年份:
    2021
  • 资助金额:
    $ 19.92万
  • 项目类别:
Colombia-U.S. Fogarty training program on the impact of emerging zoonotic and vector-borne diseases in acute undifferentiated febrile illnesses
哥伦比亚-美国
  • 批准号:
    10376263
  • 财政年份:
    2016
  • 资助金额:
    $ 19.92万
  • 项目类别:
Research Training Program on the Impact of Zoonotic and Vector-borne Viruses, Rickettsiae, and Leptospira in Acute Undifferentiated Febrile Illnesses
关于人畜共患病和媒介传播病毒、立克次体和钩端螺旋体对急性未分化发热性疾病影响的研究培训计划
  • 批准号:
    9884659
  • 财政年份:
    2016
  • 资助金额:
    $ 19.92万
  • 项目类别:
Colombia-U.S. Fogarty training program on the impact of emerging zoonotic and vector-borne diseases in acute undifferentiated febrile illnesses
哥伦比亚-美国
  • 批准号:
    10240140
  • 财政年份:
    2016
  • 资助金额:
    $ 19.92万
  • 项目类别:
Colombia-U.S. Fogarty training program on the impact of emerging zoonotic and vector-borne diseases in acute undifferentiated febrile illnesses
哥伦比亚-美国
  • 批准号:
    10577786
  • 财政年份:
    2016
  • 资助金额:
    $ 19.92万
  • 项目类别:
Hijacking of cellular pathways by novel tick-borne phlebovirus
新型蜱传白蛉病毒劫持细胞通路
  • 批准号:
    9088328
  • 财政年份:
    2015
  • 资助金额:
    $ 19.92万
  • 项目类别:
Naturally occurring human antibodies to alphavirus infection
天然存在的人类抗甲病毒感染抗体
  • 批准号:
    8512211
  • 财政年份:
    2013
  • 资助金额:
    $ 19.92万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 19.92万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了